| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 14.26 | 21.5% | 3556.4% |
| Total Income | 14.26 | 21.5% | 3556.4% |
| Expenditure | 29.65 | 48.9% | 49.8% |
| PBT | -8.70 | 73.6% | |
| Net Profit | -7.28 | 76.3% | 86.3% |
| OPM | — | ||
| NPM | -51.05% | ||
| EPS | -0.18 | 76.3% | 87.2% |
Keros Therapeutics Reports Q3 2025 Financial Results
04 May 2026 · 4 May, 8:05 am
Summary
Keros Therapeutics, Inc. issued a press release on November 5, 2025, announcing its financial results for the quarter ended September 30, 2025. The press release is furnished as an exhibit to the filing. The information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Highlights
- 1
Keros Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025.
- 2
The press release details the company's financial performance for Q3 2025.
- 3
The information is furnished as Exhibit 99.1.
Informational and educational content only. Not investment advice.